Company news
Maplight Therapeutics, Inc. (NASDAQ:MPLT) news
Maplight Therapeutics, Inc. news releases on 6ix. Latest, Oct 6, 2026: MapLight Therapeutics Celebrates Co-Founder Dr. Karl Deisseroth on Receipt of 2026…
Press releases & updates
MapLight Therapeutics Celebrates Co-Founder Dr. Karl Deisseroth on Receipt of 2026 Nobel Prize in Physiology or Medicine for the Development of Optogenetics
October 6, 2026
MapLight Therapeutics to Participate in Upcoming Investor Conference
September 9, 2026
MapLight Therapeutics Announces $150 Million Private Placement Financing
August 13, 2026
MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia
July 27, 2026
MapLight Therapeutics Announces Changes to Board of Directors
June 24, 2026
MapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder
June 21, 2026
MapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 14, 2026
MapLight Therapeutics Announces Completion of Enrollment in ZEPHYR Phase 2 Trial and Updates Expected Timing of Topline Results
May 1, 2026
MapLight Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 25, 2026
MapLight Therapeutics to Participate in Upcoming Investor Conferences
March 1, 2026
MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026
January 9, 2026
MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer’s Disease Psychosis
January 5, 2026
SandboxAQ and MapLight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS Therapies
December 16, 2025
MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress
December 4, 2025
MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
October 29, 2025
MapLight Therapeutics Announces Pricing of Initial Public Offering
October 26, 2025